News | November 25, 2014

NHLBI Conducts Study on Marfan Syndrome

Studies indicate Losartan may be an effective treatment option

NHLBI, Losartan, Marfan syndrome, atenolol

Image courtesy of Toshiba Aquilion

November 25, 2014 — Between 70 and 80 percent of patients with the connective tissue condition Marfan syndrome have aortic-root dilation, which happens when the aorta becomes too large and tears. This condition can result in serious illness and sometimes death.  A National Institutes of Health-funded study comparing treatment with widely used blood pressure medications, atenolol or losartan, in patients with Marfan syndrome who had an enlarged aortic root, found no significant difference in the rate of aortic-root dilation between the two treatment groups over three years.

The results of the “Atenolol versus Losartan in Children and Young Adults with Marfan Syndrome” study, supported by NIH’s National Heart, Lung, and Blood Institute (NHLBI), were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.

Marfan syndrome is a genetic disorder that affects connective tissue. Features of the disorder are most often found in the heart, blood vessels, bones, joints and eyes. Standard care includes frequent cardiac imaging, exercise restriction, administration of a beta-blocker such as atenolol or other medications that may decrease the rate of aortic enlargement and elective aortic-root replacement when the aortic root becomes too large. Although early diagnosis and refined medical and surgical management have improved survival, patients with Marfan syndrome continue to have high rates of complications and death from heart problems, even at a young age.

This randomized trial, which was conducted by the NHLBI’s Pediatric Heart Network, ran from 2007-2011 at 21 clinical centers in the United States, Canada and Belgium and included 608 patients aged 6 months to 25 years. 

The two drugs work in different ways. Atenolol works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure. Losartan blocks the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently.

Previous small studies had suggested that losartan might be more effective in slowing aortic-root enlargement than atenolol, which is the most common current therapy. The NIH-funded study, the largest study to date, showed that there is no important difference between the two drugs when used for this purpose. 

Although the rate of change in the aortic root did not differ between treatment groups, the severity of aortic-root enlargement decreased over time in both groups, particularly in young subjects. The cause of this outcome is unknown. Further research is necessary to evaluate the magnitude of this benefit.

The trial was supported by the by U01 grants from the NHLBI and the FDA Office of Orphan Products Development. Additional support was provided by The Marfan Foundation, Merck & Co., Inc. and Teva Canada Limited.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init